Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA7 | P43166 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 11/20 | 0.42 |
| ▸ | CTSS | P25774 | 5/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | APLNR | P35414 | 1/20 | 0.39 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21342491 | 1.00 | CA1 (0.49) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL20207292 | 1.00 | CA1 (0.49) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL21342465 | 0.83 | CA1 (0.46) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL21342494 | 0.83 | CA1 (0.46) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL17169859 | 0.83 | CA1 (0.63) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL23833195 | 0.83 | CA1 (0.46) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL15994357 | 0.83 | CA1 (0.46) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL5198000 | 0.81 | CA1 (0.51) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL3018246 | 0.81 | CA1 (0.51) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL25270811 | 0.81 | CA1 (0.51) | CA1CA2CA7CYP2D6CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046680-B1 | Heteroaryl-substituted triazoles as APJ receptor agonists | AMGEN INC. (US) | 2021-06-29 | — | — | US | disclosed |
| EP-3541805-B1 | HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS | AMGEN INC (US) | 2020-10-14 | — | — | EP | disclosed |
| WO-2018097945-A1 | HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS | AMGEN INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| US-8772450-B2 | Beta-amino acids | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772450-B2 | Beta-amino acids | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130023644-A1 | BETA-AMINO ACIDS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2013-01-24 | — | — | US | disclosed |
| US-20070154882-A1 | Beta-polypeptides that inhibit cytomegalovirus infection | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-07-05 | — | — | US | disclosed |
| US-20070154882-A1 | Beta-polypeptides that inhibit cytomegalovirus infection | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-07-05 | — | — | US | disclosed |
| US-20070123709-A1 | Beta-amino acids | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-05-31 | — | — | US | disclosed |
| US-20070123709-A1 | Beta-amino acids | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-05-31 | — | — | US | disclosed |
| WO-2006099170-A2 | BETA-POLYPEPTIDES THAT INHIBIT CYTOMEGALOVIRUS INFECTION | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2006-09-21 | — | — | WO | disclosed |
| US-6683154-B1 | UNNATURAL CATIONIC OLIGOMERS THAT HAVE NO KNOWN NATURAL COUNTERPART AND THAT DISPLAY ANTIBIOTIC ACTIVITY COMPARABLE TO THAT OF MAGAININ DERIVATIVE AGAINST AT LEAST FOUR DIFFERENT BACTERIAL SPECIES, YET EXHIBIT LOWER HEMOLYTIC ACTIVITY | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2004-01-27 | — | — | US | disclosed |
| US-6613876-B1 | Covalently linking subunit of given formula to a plurality of separable solid substrates; deprotecting; used for generating combinatorial libraries | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2003-09-02 | — | — | US | disclosed |
| WO-2003008439-A1 | ANTIMICROBIAL COMPOSITIONS CONTAINING β-AMINO ACID OLIGOMERS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2003-01-30 | — | — | WO | disclosed |
| US-20020037997-A1 | Beta-amino acids | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-03-28 | — | — | US | disclosed |
| US-6060585-A | β-polypeptide foldamers of well-defined secondary structure | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2000-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046680-B1 | Heteroaryl-substituted triazoles as APJ receptor agonists | AGTR1, AGTR2, TBXA2R | CA1 4748/4885CA2 2429/4885CA7 4159/4885 |
| US-20070123709-A1 | Beta-amino acids | BCAT1, MARCKS, YWHAZ | CA1 1425/4885CA2 3167/4885CA7 2456/4885 |
| US-20020037997-A1 | Beta-amino acids | BCAT1, BCAT2, MARCKS | CA1 1377/4885CA2 3717/4885CA7 3149/4885 |
| US-20130023644-A1 | BETA-AMINO ACIDS | BCAT1, MARCKS, YWHAZ | CA1 1425/4885CA2 3167/4885CA7 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.